Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

Oertel, Wolfgang H., Wolters, Erik, Sampaio, Cristina, Gimenez‐Roldan, Santiago, Bergamasco, Bruno, Dujardin, Max, Grosset, Donald G., Arnold, Guy, Leenders, Klaus L., Hundemer, Hans‐Peter, Lledó, Alberto, Wood, Andrew, Frewer, Paul, Schwarz, Johannes·2006·Movement Disorders

Abstract

Dopamine agonists are used as initial treatment in patients with Parkinson's disease (PD) to reduce incidence and severity of motor complications. This paradigm is based on long‐term studies, allowing “rescue” therapy with levodopa. The present strict monotherapy study (PELMOPET, the acronym for the pergolide‐versus‐L‐dopa‐monotherapy‐and‐positron‐emission‐tomography trial) evaluated the efficacy and safety of pergolide versus levodopa without levodopa “rescue” medication. This multicenter, double‐blind, randomized, 3‐year trial compared pergolide monotherapy (n = 148) with levodopa monotherapy (n = 146) in dopamine‐naive patients with early PD (Hoehn and Yahr stage 1–2.5). Primary efficacy measures were clinical efficacy, severity and time to onset of motor complications, and disease progression. During the 3 years, severity of motor complications was significantly lower and time to onset of dyskinesia was significantly delayed in the group receiving pergolide (3.23 mg/day) compared with those receiving levodopa (504 mg/day). However, time to onset of motor complications was not longer in patients receiving pergolide after 3 years. Symptomatic relief (assessed by Unified Parkinson's Disease Rating Scale [UPDRS], UPDRS II, and III, Clinical Global Impressions [CGI] severity, and CGI and Patient Global Impressions [PGI] improvement) was significantly greater in patients receiving levodopa. Adverse events led to discontinuation of therapy in 17.6% of pergolide patients and 9.6% of levodopa patients. This is the first study comparing strict monotherapy with a dopamine agonist versus levodopa in previously untreated early PD. In principle, both levodopa and a dopamine agonist such as pergolide seem to be suitable options as initial PD therapy. The choice remains with the treating physician based on the different efficacy and adverse event profiles. © 2005 Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.20724

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 210

Metadata

Authors
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., Lledó, A., Wood, A., Frewer, P., & Schwarz, J.
Venue
Movement Disorders
Publisher
Wiley
Published
2006-03
Volume
21
Issue
3
Pages
343-353
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W2159726703
Cited by
210
References
2
FWCI
10.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. https://app.cochat.ai/papers/10.1002/mds.20724
The paper
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., Lledó, A., Wood, A., Frewer, P., & Schwarz, J. (2006). Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Movement Disorders. https://doi.org/10.1002/mds.20724

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.